JP2020526478A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526478A5
JP2020526478A5 JP2019565454A JP2019565454A JP2020526478A5 JP 2020526478 A5 JP2020526478 A5 JP 2020526478A5 JP 2019565454 A JP2019565454 A JP 2019565454A JP 2019565454 A JP2019565454 A JP 2019565454A JP 2020526478 A5 JP2020526478 A5 JP 2020526478A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
light chain
chain containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019565454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526478A6 (ja
JP7220161B2 (ja
JP2020526478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/000645 external-priority patent/WO2018215835A1/en
Publication of JP2020526478A publication Critical patent/JP2020526478A/ja
Publication of JP2020526478A6 publication Critical patent/JP2020526478A6/ja
Publication of JP2020526478A5 publication Critical patent/JP2020526478A5/ja
Application granted granted Critical
Publication of JP7220161B2 publication Critical patent/JP7220161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019565454A 2017-05-26 2018-05-29 抗CD47x抗メソテリン抗体およびそれを使用する方法 Active JP7220161B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511669P 2017-05-26 2017-05-26
US62/511,669 2017-05-26
US201762550387P 2017-08-25 2017-08-25
US62/550,387 2017-08-25
PCT/IB2018/000645 WO2018215835A1 (en) 2017-05-26 2018-05-29 Anti-cd47 x anti-mesothelin antibodies and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2020526478A JP2020526478A (ja) 2020-08-31
JP2020526478A6 JP2020526478A6 (ja) 2021-01-07
JP2020526478A5 true JP2020526478A5 (enExample) 2021-07-26
JP7220161B2 JP7220161B2 (ja) 2023-02-09

Family

ID=63168446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019565454A Active JP7220161B2 (ja) 2017-05-26 2018-05-29 抗CD47x抗メソテリン抗体およびそれを使用する方法

Country Status (6)

Country Link
US (1) US11260117B2 (enExample)
EP (1) EP3630167A1 (enExample)
JP (1) JP7220161B2 (enExample)
AU (2) AU2018272311B2 (enExample)
CA (1) CA3065008A1 (enExample)
WO (1) WO2018215835A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3086098A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
WO2020114615A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Bispecific antibodies binding factor ixa and factor x
WO2020115283A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Bispecific antibodies binding factor ixa and factor x
EP3831849A1 (en) * 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
JP7369297B2 (ja) * 2019-12-17 2023-10-25 ファイザー・インク Cd47、pd-l1に特異的な抗体、およびその使用
US20230391867A1 (en) * 2020-11-17 2023-12-07 Shenzhen Enduring Biotech, Ltd. Long acting bi-specific t cell engagers targeting cd3 and cd47
JP2024512574A (ja) 2021-03-22 2024-03-19 ノビミューン エスアー Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
US20240336681A1 (en) * 2021-07-30 2024-10-10 Ludwig-Maximilians-Universität München Anti-cd47 antibodies and use thereof
WO2023006390A1 (en) * 2021-07-30 2023-02-02 Ludwig-Maximilians-Universität München Mesothelin antibodies and use thereof
CA3248133A1 (en) 2022-01-24 2023-07-27 Novimmune Sa COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS
CA3251683A1 (en) * 2022-02-18 2023-08-24 Adivo Gmbh FELINE ANTIBODY LIBRARIES
EP4490192A1 (en) * 2022-03-07 2025-01-15 Novimmune S.A. Cd28 bispecific antibodies for targeted t cell activation
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
IL328469A (en) * 2023-11-28 2026-07-01 Novimmune Sa Method for treating disease using antibodies against CD47 and against mesothelin as a single agent and in combination with antibodies against PD-1
WO2026082966A1 (en) * 2024-10-18 2026-04-23 Novimmune Sa Methods of treating disease using anti-cd47 x anti-mesothelin antibodies in combination with chemotherapy
WO2026152120A2 (en) 2025-01-13 2026-07-16 HCW Biologics, Inc. Chimeric polypeptides and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2010249470B2 (en) 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
EP2513312B1 (en) 2009-12-17 2015-03-18 NovImmune SA Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
ES2767135T3 (es) 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Similar Documents

Publication Publication Date Title
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP2020500538A5 (enExample)
JP2020515508A5 (enExample)
JP2021531254A5 (enExample)
RU2018128215A (ru) Антитела против mica
JP2014530017A5 (enExample)
JP2010536384A5 (enExample)
RU2010123888A (ru) Axl-антитела
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
JP2020500508A5 (enExample)
JP2019535763A5 (enExample)
JP2024511137A5 (enExample)
JP2010502183A5 (enExample)
JP2018521638A5 (enExample)
JP2016020389A5 (enExample)
NZ602621A (en) Antibodies against csf-1r
JP2022530404A5 (enExample)
FI3922645T3 (fi) Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja
IL261666B1 (en) Binding proteins and methods of use thereof
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
JP2011505146A5 (enExample)
JP2018512124A5 (enExample)
JP2009541204A5 (enExample)
JP2013544756A5 (enExample)
JP2021501579A5 (enExample)